- Home
- TXMD vs CCM Comparison
TXMD vs CCM Comparison
Compare TXMD & CCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TXMD | CCM |
|---|---|---|
| Founded | 2008 | 1997 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 21.3M |
| IPO Year | 2012 | 2009 |
Fundamental Metrics
Financial Performance| Metric | TXMD | CCM |
|---|---|---|
| Price | $2.07 | $3.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 20.5K | ★ 23.9K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.68 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $1,761,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $106.50 | ★ N/A |
| Revenue Growth | ★ 35.25 | N/A |
| 52 Week Low | $0.99 | $3.18 |
| 52 Week High | $2.95 | $6.98 |
Technical Indicators
Market Signals| Indicator | TXMD | CCM |
|---|---|---|
| Relative Strength Index (RSI) | 41.59 | 38.51 |
| Support Level | $1.95 | $3.18 |
| Resistance Level | $2.16 | $4.24 |
| Average True Range (ATR) | 0.07 | 0.32 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 14.78 | 31.61 |
Price Performance
Historical ComparisonAbout TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
About CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.